Carboplatin, Gemcitabine, and Thalidomide in Patients Undergoing Surgery for Stage II or III Non-Small Cell Lung Cancer

Inclusion Criteria: * Histologically or cytologically confirmed non-small cell lung cancer (NSCLC), including any of the following histologic subtypes: * Squamous cell carcinoma * Adenocarcinoma * Large cell undifferentiated carcinoma * Stage II or IIIA disease * Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral Computerized Axial Tomography (CT) scan * No tumor involving the superior sulcus (e.g., Pancoast tumor) * Karnofsky performance status 70-100% * Absolute neutrophil count ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 * Creatinine ≤ 2 mg/dL * Bilirubin \< 2 mg/dL * Aspartate aminotransferase (AST) \< 3 times upper limit of normal Exclusion Criteria: * Pregnant or nursing * No nursing during and for ≥ 4 weeks after completion of study treatment * Positive pregnancy test * Fertile female patients must use 2 effective methods of contraception 4 weeks before, during, and for 4 weeks after completion of study treatment * Fertile male patients must use effective barrier contraception during and for 4 weeks after completion of study treatment * Blood, sperm, or ova donation during study treatment * Post obstructive pneumonia * Other serious infection or medical illness that would preclude study participation * Other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or other malignancy that is unlikely to affect survival for the next 3 years * Less than 5 years since prior resection of lung disease * Prior systemic chemotherapy or radiotherapy for non-small cell lung cancer (NSCLC) * Other concurrent chemotherapy or radiotherapy * Concurrent hormonal therapy or immunotherapy * Other concurrent anticancer therapy * Other concurrent investigational agents * Concurrent participation in another clinical study